Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Safety Is The Hub For Social Networking Site iGuard; Registries Will Fund It

Executive Summary

The public launch of the online patient forum iGuard on April 28 emphasizes the promise that social networking sites have to help companies and regulators learn about real-world use of drugs, but also underscores the uncertainties that surround the new medium

You may also be interested in...



Social Networking Sites: Small Step For Firms, Giant Leap For Research

As social networking Web sites court big pharma with new services, firms now must decide whether such forums can play a useful role in collecting data and monitoring markets

Social Networking Sites: Small Step For Firms, Giant Leap For Research

As social networking Web sites court big pharma with new services, firms now must decide whether such forums can play a useful role in collecting data and monitoring markets

Pfizer’s Drug Safety Web Site Aims To Reclaim Risk Communication Authority

BOSTON-Pfizer's new Medicine Safety Web site is the first attempt by a pharmaceutical company to reclaim authority over risk communication from FDA

Related Content

UsernamePublicRestriction

Register

PS049567

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel